Indian equities are expected to consolidate in a narrow range over the next few months as corporate earnings remain the missing link, says Trideep Bhattacharya of Edelweiss MF. While macro headwinds have eased and policy momentum has improved, meaningful earnings revival is seen only in H2FY26. Consumption, financials, and defence are key sectors to watch, with selective midcap exposure advised.
Corona Remedies and Wakefit Innovations to list tomorrow; GMP suggests sharp upside for pharma play
Corona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expectations backed by robust subscriptions and